Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yong Shim

Showing results (261-270 of 290) with videos related to

Pageof 29
Sort By:
Cancer Chemotherapy and Pharmacology|August 7, 2013
A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancerChang Dong Yeo, Sang Haak Lee, Ju Sang Kim, et al.
Nature Communications|July 10, 2025
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part BKeun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, et al.
Journal of Gastric Cancer|May 2, 2023
A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical ObservationGuk Jin Lee, Hyunho Kim, Sung Shim Cho, et al.
Translational Lung Cancer Research|August 12, 2022
Totality outcome of afatinib sequential treatment in patients with <i>EGFR</i> mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22Hyun Ae Jung, Min Hee Hong, Hyun Woo Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|September 14, 2010
A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancerChin Kook Rhee, Sang Haak Lee, Ju Sang Kim, et al.
Scientific Reports|November 13, 2024
Elimination of olfactory sensory neurons by zinc sulfate inoculation prevents SARS-CoV-2 infection of the brain in K18-hACE2 transgenic miceJi-Hun Lee, Eun-Seon Yoo, Na-Won Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLCEun Ji Lee, Ji Ae Ko, Min-Je Kim, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 26, 2015
Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12Jong Hoon Lee, Dae Yong Kim, Sung Hwan Kim, et al.
Cancer|December 8, 2021
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patientsHyun Cheol Chung, Yoon-Koo Kang, Zhendong Chen, et al.
Nature Nanotechnology|June 16, 2015
Bright visible light emission from grapheneYoung Duck Kim, Hakseong Kim, Yujin Cho, et al.
Pageof 29

Showing results (261-270 of 290) with videos related to

Sort By:
Pageof 29
Cancer Chemotherapy and Pharmacology|August 7, 2013
A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancerChang Dong Yeo, Sang Haak Lee, Ju Sang Kim, et al.
Nature Communications|July 10, 2025
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part BKeun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, et al.
Journal of Gastric Cancer|May 2, 2023
A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical ObservationGuk Jin Lee, Hyunho Kim, Sung Shim Cho, et al.
Translational Lung Cancer Research|August 12, 2022
Totality outcome of afatinib sequential treatment in patients with <i>EGFR</i> mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22Hyun Ae Jung, Min Hee Hong, Hyun Woo Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|September 14, 2010
A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancerChin Kook Rhee, Sang Haak Lee, Ju Sang Kim, et al.
Scientific Reports|November 13, 2024
Elimination of olfactory sensory neurons by zinc sulfate inoculation prevents SARS-CoV-2 infection of the brain in K18-hACE2 transgenic miceJi-Hun Lee, Eun-Seon Yoo, Na-Won Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLCEun Ji Lee, Ji Ae Ko, Min-Je Kim, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 26, 2015
Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12Jong Hoon Lee, Dae Yong Kim, Sung Hwan Kim, et al.
Cancer|December 8, 2021
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patientsHyun Cheol Chung, Yoon-Koo Kang, Zhendong Chen, et al.
Nature Nanotechnology|June 16, 2015
Bright visible light emission from grapheneYoung Duck Kim, Hakseong Kim, Yujin Cho, et al.
Pageof 29